Ambry has continued to provide clinicians with the most relevant and useful information to encourage education about the benefits of genetic testing for patients and ways to streamline genetic testing in clinical practice.

At the 2017 SSO Annual Cancer Symposium, Ambry hosted the presentation “On the Cutting Edge: Sharpening Your Genetic Awareness with Impactful Tools for your Practice,” featuring speakers Robina Smith, MD, EMBA, Ambry’s Director of Medical Affairs, and Michelle Jackson, MS, CGC, Ambry’s Oncology Product Manager, who discussed several educational objectives on streamlining genetic testing.

Dr. Smith highlighted the clinical utility of genetic testing by providing four case examples on four different genes. She walked the audience through the presentation of a patient in a clinic setting while highlighting the typical vital signs utilized by clinicians, while incorporating genetic testing.

“For all physicians, it is expected that an elevated risk (i.e. vital signs, signs & symptoms) of any disease, for which there is screening, prevention and treatment, needs immediate action,” said Dr. Smith. “The same philosophy applies to a deleterious genetic mutation. Think of assessing your patients risk for hereditary cancers as the ‘6th vital sign.’”

Ms. Jackson spoke on several of Ambry’s genetic testing panels that offer a broad scope of results. The panels, which highlighted many options from the hereditary cancer test menu, offer a comprehensive testing option for clinicians and their patients.

“At Ambry, we are driven to give physicians the most advanced testing information available so they can determine the best treatment options for their patients,” said Ms. Jackson.  “Conveying our mission, history, and comprehensive hereditary cancer testing menu demonstrates why we do what we do and who we do it for. We ultimately want to help patients find answers.”

{Learn more from Ms. Jackson: “Research Shows BRCA2 May Be Linked To Brain Tumors”}

Dr. Smith also focused on the utility of several clinical tools, which were incorporated throughout the presentation with case examples. For instance, if a clinician sees a healthy woman inquiring about hereditary breast and ovarian cancer, Dr. Smith recommended utilizing Ambry’s risk assessment models through Progeny and Clinician Management Resources, which follow National Comprehensive Cancer Network® (NCCN®) guidelines.

Ambry offers a variety of clinical tools and resources that can aid clinician’s knowledge base and patient communication. For more information about some of the available tools, click here.

In addition, Ambry offers several comprehensive genetic testing options for a wide variety of hereditary cancers. Panels such as CancerNext and CancerNext-Expanded analyze genes that are associated with hereditary breast, ovarian, uterine, prostate, colorectal and other cancers.

For a complete list of Ambry’s hereditary cancer testing options, click here.